NASDAQ:URGN - Urogen Pharma Stock Price, Forecast & News

Urogen Pharma trades on the NASDAQ under the ticker symbol "URGN."

Urogen Pharma Ltd (NASDAQ:URGN) issued its quarterly earnings results on Tuesday, November, 12th. The company reported ($1.06) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($1.26) by $0.20. View Urogen Pharma's Earnings History.

Urogen Pharma is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Urogen Pharma.

8 brokerages have issued twelve-month target prices for Urogen Pharma's stock. Their forecasts range from $37.00 to $75.00. On average, they expect Urogen Pharma's stock price to reach $50.14 in the next twelve months. This suggests a possible upside of 69.5% from the stock's current price. View Analyst Price Targets for Urogen Pharma.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Urogen Pharma in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Urogen Pharma.

News stories about URGN stock have been trending neutral on Tuesday, InfoTrie reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Urogen Pharma earned a news sentiment score of 0.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an impact on the company's share price in the next few days. View News Stories for Urogen Pharma.

Urogen Pharma saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 2,120,000 shares, an increase of 17.8% from the January 15th total of 1,800,000 shares. Based on an average daily volume of 179,400 shares, the short-interest ratio is presently 11.8 days. Currently, 12.5% of the company's shares are short sold. View Urogen Pharma's Current Options Chain.

Some companies that are related to Urogen Pharma include Karuna Therapeutics (KRTX), Epizyme (EPZM), Ra Pharmaceuticals (RARX), Synthorx (THOR), Turning Point Therapeutics (TPTX), Prestige Consumer Healthcare (PBH), Principia Biopharma (PRNB), Aurinia Pharmaceuticals (AUPH), Pacira Biosciences (PCRX), Xencor (XNCR), Cambrex (CBM), Eidos Therapeutics (EIDX), Esperion Therapeutics (ESPR), Ironwood Pharmaceuticals (IRWD) and Heron Therapeutics (HRTX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Urogen Pharma investors own include Kite Pharma (KITE), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Nektar Therapeutics (NKTR), Intercept Pharmaceuticals (ICPT), AbbVie (ABBV), BP Prudhoe Bay Royalty Trust (BPT), Crispr Therapeutics (CRSP) and Immunomedics (IMMU).

(URGN) raised $46 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 3,500,000 shares at $12.00-$14.00 per share. Jefferies and Cowen and Company acted as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.

Urogen Pharma's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Wildcat Capital Management LLC (5.53%), Migdal Insurance & Financial Holdings Ltd. (3.53%), Credit Suisse AG (3.20%), State Street Corp (1.97%), FMR LLC (1.51%) and Meitav Dash Investments Ltd. (1.30%). Company insiders that own Urogen Pharma stock include Elizabeth A Barrett, Mark Schoenberg, Peter P Pfreundschuh and Stephen Mullennix. View Institutional Ownership Trends for Urogen Pharma.

URGN stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Migdal Insurance & Financial Holdings Ltd., Goldman Sachs Group Inc., Bank Hapoalim BM, Private Advisors LLC, New York State Common Retirement Fund, Victory Capital Management Inc. and Quantbot Technologies LP. Company insiders that have sold Urogen Pharma company stock in the last year include Mark Schoenberg, Peter P Pfreundschuh and Stephen Mullennix. View Insider Buying and Selling for Urogen Pharma.

URGN stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Wildcat Capital Management LLC, Jane Street Group LLC, Credit Suisse AG, State Street Corp, Meitav Dash Investments Ltd., California Public Employees Retirement System and UBS Asset Management Americas Inc.. Company insiders that have bought Urogen Pharma stock in the last two years include Elizabeth A Barrett and Mark Schoenberg. View Insider Buying and Selling for Urogen Pharma.

Shares of URGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of URGN stock can currently be purchased for approximately $29.59.

Urogen Pharma has a market capitalization of $618.43 million and generates $1.13 million in revenue each year. The company earns $-75,660,000.00 in net income (profit) each year or ($4.80) on an earnings per share basis. Urogen Pharma employs 70 workers across the globe.View Additional Information About Urogen Pharma.

The official website for Urogen Pharma is http://www.urogen.com/.

Urogen Pharma's mailing address is 499 Park Avenue, New York NY, 10014. The company can be reached via phone at 646-768-9780 or via email at [email protected]